Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd. - Common Shares
(NQ:
ROIV
)
23.41
-0.40 (-1.70%)
Streaming Delayed Price
Updated: 3:36 PM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
February 13, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
January 30, 2024
From
Roivant Sciences
Via
GlobeNewswire
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
↗
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
↗
January 10, 2024
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via
Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
↗
January 02, 2024
Via
Benzinga
Analyst Ratings for Roivant Sciences
↗
December 12, 2023
Via
Benzinga
8 Analysts Have This to Say About Roivant Sciences
↗
November 14, 2023
Via
Benzinga
Earnings Scheduled For February 13, 2024
↗
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
Roivant Sciences Earnings Preview
↗
February 12, 2024
Via
Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
↗
December 21, 2023
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in
Via
Benzinga
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From
Roivant Sciences
Via
GlobeNewswire
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
December 20, 2023
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Via
Benzinga
Topics
Stocks
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
December 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Earnings Preview
↗
November 10, 2023
Via
Benzinga
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
↗
November 27, 2023
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)
Via
Benzinga
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
November 27, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
November 13, 2023
From
Roivant Sciences
Via
GlobeNewswire
Earnings Scheduled For November 13, 2023
↗
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
November 10, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
October 30, 2023
From
Roivant Sciences
Via
GlobeNewswire
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
↗
October 24, 2023
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
Via
The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
↗
October 23, 2023
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV.
Via
InvestorPlace
PINS Stock Pops as Stifel Upgrades Pinterest
↗
October 23, 2023
Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target.
Via
InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
↗
October 23, 2023
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.
Via
InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
↗
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
↗
October 23, 2023
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
Via
Benzinga
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
↗
October 23, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set...
Via
Benzinga
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
↗
October 23, 2023
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
October 23, 2023
From
Roivant Sciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
